<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115734</url>
  </required_header>
  <id_info>
    <org_study_id>CARNUSI</org_study_id>
    <nct_id>NCT05115734</nct_id>
  </id_info>
  <brief_title>Acylcarnitine Profile After Intensive Care</brief_title>
  <official_title>Acylcarnitine Profile After Intensive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the acylcarnitine profile of critically ill survivors of a&#xD;
      prolonged stay in ICU with the profile of survivors of short ICU length of stay. The second&#xD;
      aim is to assess the evolution of the acylcarnitine profile over time in survivors of a&#xD;
      prolonged ICU stay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a retrospective analysis focused on survivors of an ICU stay of 7 days or more, we showed&#xD;
      that during the week following discharge, carnitine deficiency was rare, but acylcarnitine&#xD;
      profile was altered, with an abnormal acylcarnitine/carnitine ratio in more than 25% of the&#xD;
      population.&#xD;
&#xD;
      Carnitine has a key role in cellular energy metabolism and is a a biomarker of the&#xD;
      mitochondria function. Moreover, mitochondrial function is proven to be severely impaired in&#xD;
      critically ill patients and mitochondrial dysfunction has been linked to post-ICU disorders.&#xD;
&#xD;
      In this context, it is relevant to study the evolution over time of the acylcarnitine profile&#xD;
      in ICU survivors of a prolonged ICU stay. It is also relevant to compare the same profile&#xD;
      between survivors of a prolonged and a shorter ICU stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 3, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acylcarnitine profile</measure>
    <time_frame>During the 5 first days following ICU discharge</time_frame>
    <description>Serum acylcarnitine profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acylcarnitine profile</measure>
    <time_frame>1 month following ICU discharge</time_frame>
    <description>Serum acylcarnitine profile in long stayers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acylcarnitine profile</measure>
    <time_frame>3 month following ICU discharge</time_frame>
    <description>Serum acylcarnitine profile in long stayers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acylcarnitine profile</measure>
    <time_frame>12 month following ICU discharge</time_frame>
    <description>Serum acylcarnitine profile in long stayers</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Critical Care</condition>
  <condition>Carnitine Metabolism Disturbances</condition>
  <arm_group>
    <arm_group_label>Short stayers</arm_group_label>
    <description>Determination of the acylcarnitine profile during the 5 days following discharge of a short stay in ICU (maximum 2 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long stayers</arm_group_label>
    <description>Determination of the acylcarnitine profile during the year following discharge of a prolonged stay in ICU (7 days or more)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum acylcarnitine profiling</intervention_name>
    <description>Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.&#xD;
Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA).</description>
    <arm_group_label>Long stayers</arm_group_label>
    <arm_group_label>Short stayers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Group short stayers: Critically ill patients with ICU length of stay of 2 days:&#xD;
             patients admitted in ICU after a scheduled cardiac surgery with sternotomy&#xD;
&#xD;
          -  Group long stayers: Critically ill patients with ICU length of stay of at least 7&#xD;
             days, whatever the critically illness&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group short stayers: ICU length of stay of 2 days&#xD;
&#xD;
          -  Group long stayers: ICU length of stay of at least 7 days&#xD;
&#xD;
        Exclusion criteria: patient refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Françoise Rousseau, MD, PhD</last_name>
    <phone>+3243667495</phone>
    <email>afrousseau@chuliege.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François Boemer, PhD</last_name>
    <email>f.boemer@chuliege.be</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Anne-Françoise Rousseau</investigator_full_name>
    <investigator_title>Head of Clinic</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

